Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Mass device reclassification

This article was originally published in The Gray Sheet

Executive Summary

Mass device reclassification: FDA is developing a concept paper for the mass reclassification of 40-50 preamendments Class III devices that will go through its reengineered regulation development process. The majority of the devices are those for which FDA has called for data under Sec. 515(i) of the device law. FDA plans on issuing a second mass reclassification for the remaining 515(i) devices for which data is due on Feb. 14 and Aug. 14, 1998. The agency also plans to propose reclassification of roughly 10 515(b) devices on an individual basis and a mass call for PMAs for 515(b) devices that have fallen into disuse...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel